Voyager Therapeutics, Inc. (NASDAQ: VYGR)

Voyager Therapeutics, Inc., a prominent player in the biotechnology industry, is dedicated to transforming the trajectory and eventually curing neurological disorders by harnessing human genetics. The company's portfolio encompasses programs for Alzheimer's disease, amyotrophic lateral sclerosis (ALS), Parkinson's disease, and other central nervous system diseases. Voyager's mission is to develop disease-modifying neurogenetic medicines through the identification of validated targets, advancement of multiple therapeutic modalities, and delivery to the appropriate areas within the central nervous system.

The company's primary offerings are gene therapies, including anti-tau antibodies and adeno-associated virus (AAV) gene therapy candidates. Voyager's main clients are pharmaceutical companies such as Alexion, AstraZeneca Rare Disease, Novartis, Neurocrine Biosciences, and Sangamo Therapeutics.

Voyager's product development strategy is multifaceted, with programs spanning antibodies and gene therapies. One notable program is the Anti-Tau Antibody Program (VY-TAU01), aimed at treating Alzheimer's disease. This program seeks to reduce toxic tau aggregates, a central aspect of the disease. Preclinical studies have demonstrated that VY-TAU01 targets the mid-domain and C-terminus of the tau protein with high affinity, exhibiting robust activity in mouse models. Voyager plans to submit an Investigational New Drug (IND) application to the FDA in the first half of 2024 and initiate a Phase 1 clinical trial in 2024.

In the gene therapy realm, Voyager is developing a program for the treatment of ALS caused by the SOD1 mutation. This program utilizes a blood-brain barrier (BBB)-penetrant, central nervous system (CNS)-tropic TRACER Capsid to deliver a vectorized small interfering RNA (siRNA) construct targeting SOD1. Preclinical studies have shown that this program achieves robust SOD1 knockdown across all levels of the spinal cord and significant improvements in motor performance, body weight, and survival in an SOD1-ALS mouse model. Voyager intends to submit an IND application to the FDA in mid-2025 and initiate a Phase 1 clinical trial in subjects with SOD1 ALS.

Voyager is also developing a gene therapy program for the treatment of Alzheimer's disease, employing an intravenously delivered TRACER Capsid containing a vectorized siRNA targeting tau mRNA. Preclinical studies have revealed that this program achieves broad AAV distribution across multiple brain regions and dose-dependent reductions in tau mRNA levels of up to 90%. Voyager plans to file an IND in 2026.

The company's competitive edge lies in its robust pipeline of gene therapy candidates for various neurological disorders and its proficiency in gene therapy. Voyager's TRACER Capsid discovery platform, a broadly applicable, RNA-based screening platform, facilitates the rapid discovery of AAV capsids with robust penetration of the blood-brain barrier and enhanced CNS tropism in multiple species, including non-human primates. This platform has been instrumental in generating multiple families of TRACER Capsids with robust CNS tropism following intravenous delivery.

Voyager Therapeutics is a publicly traded company listed on the NASDAQ stock exchange under the ticker symbol VYGR. The company has secured substantial funding from various investors and maintains a strong cash position, enabling it to continue advancing its pipeline of gene therapy candidates.